Theravance Biopharma, Inc. (FRA:0TB)

Market Cap	807.81M +96.3%
Revenue (ttm)	68.46M +27.1%
Net Income	25.01M
EPS	0.49
Shares Out	n/a
PE Ratio	32.30
Forward PE	45.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	16.90
Previous Close	17.50
Day's Range	16.90 - 16.90
52-Week Range	7.30 - 17.50
Beta	n/a
RSI	44.72
Earnings Date	Feb 23, 2026

About Theravance Biopharma

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the de...

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 97
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0TB

Financial Performance

In 2024, Theravance Biopharma's revenue was $64.38 million, an increase of 12.12% compared to the previous year's $57.42 million. Losses were -$56.42 million, 2.22% more than in 2023.

Financial numbers in USD